Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02638259 · ClinicalTrials.gov registry record · Phase 3
Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis
A Phase 3 study, sponsored by Sandoz.
- Completed
- Registry status
- Phase 3
- Development phase
- 376
- Enrollment target
NCT02638259 is a Phase 3 study that has completed, run by Sandoz. The registered enrollment target is 376 participants.
The verdict
NCT02638259, a Phase 3 study, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 376 participants
- Enrollment target
Study Summary
Demonstrate equivalent efficacy of GP2015 and EU-authorized Enbrel in patients with moderate to severe, active (RA) who had an inadequate response to disease modifying anti-rheumatic drugs (DMARD) including methotrexate (MTX).
Interventions
- DRUG GP2015
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2015-02-21 |
| Est. Completion | 2017-06-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02638259
The ClinicalTrials.gov registry entry for NCT02638259 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sandoz, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GP2015 is the first listed.
NCT02638259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02638259 about?
NCT02638259 is a clinical study titled "Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis". Demonstrate equivalent efficacy of GP2015 and EU-authorized Enbrel in patients with moderate to severe, active (RA) who had an inadequate response to disease modifying anti-rheumatic drugs (DMARD) including methotrexate (MTX).
What is the current status of trial NCT02638259?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 376 participants. The study started on 2015-02-21. Estimated completion is 2017-06-12.
What interventions are being tested in trial NCT02638259?
The interventions under investigation include: GP2015 (DRUG).
Who is sponsoring clinical trial NCT02638259?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.